Oncotelic Therapeutics Inc. (OTCQB: OTLC) has introduced PDAOAI, an evidence-interrogation platform designed to address a core challenge in biotech research: reducing training-set bias and building transparent, reproducible chains from question to evidence to hypothesis. The platform indexes over 125,000 PubMed abstracts on TGF-β signaling, enabling researchers to interrogate the evidence for testable, auditable hypotheses rather than rely on black-box predictions.
Recent industry coverage places Oncotelic alongside Rockwell Automation, Emerson Electric, Thermo Fisher Scientific, and Danaher as contributors to the pharmaceutical sector’s shift toward AI-integrated operations. This shift comes as regulatory agencies raise expectations around data integrity and traceability, and the industry moves from retrospective audits toward continuous, AI-enabled monitoring systems.
According to the company, the PDAOAI platform takes a retrieval-and-interrogation approach rather than relying on traditional predictive models trained to replicate historical datasets. It organizes and connects large volumes of biomedical literature, allowing researchers to identify patterns and generate testable hypotheses with direct links to the underlying evidence. This approach supports the growing need for defensible documentation in an environment where scientific literature expands rapidly and regulatory demands require continuous monitoring.
Pharmaceutical research and manufacturing are undergoing a structural transition. Manual processes and isolated datasets are no longer sufficient as the availability of large-scale biomedical data and tools to interrogate it at scale reshape drug discovery. Oncotelic’s PDAOAI platform fits into this broader AI transformation by providing a tool that surfaces testable research hypotheses from the global TGF-β literature.
For more information on Oncotelic Therapeutics and the latest news, visit the company’s newsroom at ibn.fm/OTLC. BioMedWire, a specialized communications platform focusing on the Biotechnology, Biomedical Sciences, and Life Sciences sectors, is one of over 75 brands within the Dynamic Brand Portfolio @IBN that delivers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release distribution, social media distribution via IBN to millions of followers, and a full array of tailored corporate communications solutions.
BioMedWire is where breaking news, insightful content, and actionable information converge. For more information, visit https://www.BioMedWire.com and see full terms of use and disclaimers at https://www.BioMedWire.com/Disclaimer.
